查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974018

双特异性抗体市场分析及预测（至2035年）：按类型、产品、技术、成分、应用、最终用户、製程、部署、功能及阶段划分

Bispecific Antibodies Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, End User, Process, Deployment, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5个工作天内

价格
简介目录

双特异性抗体市场预计将从2024年的123亿美元成长到2034年的256亿美元，复合年增长率约为7.6%。双特异性抗体市场包括旨在结合两种不同抗原的治疗药物，可增强标靶治疗在肿瘤学、免疫学和感染疾病的疗效。这些创新分子能够提高特异性并减少脱靶效应。基因工程的进步和癌症发生率的上升是推动市场成长的主要因素，促进了新型治疗方法的开发以及生物製药公司之间的策略联盟。

受标靶治疗和免疫肿瘤学进展的推动，双特异性抗体市场正经历强劲成长。肿瘤领域引领市场，其中骨髓恶性肿瘤因其巨大的治疗潜力而占据主导地位。固态肿瘤领域紧随其后，反映出研究投入和临床试验的增加。在各细分领域中，基于CD3的双特异性抗体表现最佳，这得益于其有效活化T细胞的能力。 CD20/CD3双特异性抗体因其在B细胞恶性肿瘤的疗效，预计未来将备受关注。自体免疫疾病领域也呈现成长势头，双特异性抗体为该领域提供了新的治疗选择。在该领域，针对TNF-α和IL-6的抗体正成为极具潜力的候选药物。抗体工程和双特异性形式（例如双亲和性重定向）的技术进步正在提高治疗效果和安全性。生物製药公司之间的策略联盟和伙伴关係正在加速开发平臺，促进创新，并拓展市场格局。对个人化医疗的需求进一步推动了市场成长。

市场区隔
类型 T细胞结合抗体、NK细胞结合抗体、抗体药物复合体（ADC）、亲和性标靶化抗体、双功能抗体、三功能抗体
产品 治疗性抗体、诊断性抗体、研究性抗体、客製化抗体
科技 融合瘤技术、噬菌体展示技术、基因转殖小鼠技术、单B细胞技术
成分 轻链、重链、Fc区、抗原结合位点
目的 肿瘤学、自体免疫疾病、感染疾病、心血管疾病、神经系统疾病
最终用户 製药公司、生技公司、研究机构、受託研究机构
过程 药物发现、开发、生产、品管和监管核准。
发展 内部开发、外包、混合模式
功能 标靶结合、免疫调节、讯号传导
步 临床前研究、临床试验、商业化

市场概况：

由于创新定价策略和突破性产品的推出，双特异性抗体市场正经历市场份额的动态重组。各公司正专注于策略性产品发布，以满足尚未满足的市场需求并增强自身竞争优势。市场格局的特点是拥有强大的产品平臺，专注于新的治疗领域，这种策略方针正在推动竞争格局的形成。定价在市场渗透和消费者接受度方面发挥着至关重要的作用。双特异性抗体市场的竞争异常激烈，各大製药巨头都在争夺主导。基准研究表明，法规结构对市场趋势有显着的影响。北美和欧洲处于领先地位，严格的监管标准塑造市场动态。与此同时，亚太地区正经历投资激增和监管放鬆，营造出有利于成长的环境。这些因素的相互作用为寻求把握新成长机会的相关人员创造了一个复杂而又充满希望的局面。

主要趋势和驱动因素：

在生物技术进步和癌症发病率上升的推动下，双特异性抗体市场正经历强劲成长。这些抗体因其标靶治疗的优势而备受青睐，它们在提高疗效的同时，也能最大限度地减少副作用。关键趋势包括新型双特异性结构的开发、特异性和功能的提升，以及肿瘤治疗应用范围的扩展。製药公司正大力投资研发，以创造创新的双特异性抗体平台。这些投资正在加速产品平臺的开发，并加快监管核准。策略联盟和伙伴关係的增加正在增强技术能力并扩大市场。此外，对个人化医疗的日益关注也为双特异性抗体满足未被满足的医疗需求创造了机会。新兴市场由于医疗保健支出的成长和基础设施的进步，蕴藏着巨大的潜力。对先进生物製药日益增长的需求为市场相关人员带来了盈利的利润。随着人们对双特异性抗体的认识不断提高，在技术创新和策略性产业合作的推动下，预计该市场将实现持续成长。

压制与挑战：

双特异性抗体市场面临许多重大限制与挑战。其中一项主要挑战是其复杂的生产工艺，这需要专门的设施和专业技术，导致生产成本增加。这种复杂性会阻碍规模化生产，并限制其满足不断增长的需求的能力。监管障碍也是一项重大挑战。双特异性抗体严格的核准流程会延迟其进入市场，并增加研发成本。企业必须应对因地区而异的复杂法规环境，这使得国际扩张举步维艰。此外，该市场还面临来自传统单株抗体和其他新兴治疗方法的激烈竞争。这些替代疗法通常具有成熟的疗效和安全性，使得双特异性抗体难以立足。另外，缺乏熟悉双特异性抗体疗法开发和管理的专业人才也是一项挑战。人才短缺会减缓创新，阻碍该领域的发展。最后，报销问题也是一大障碍。双特异性抗体的高成本使得企业难以获得保险公司的报销，这可能会限制病患的用药机会和市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • T细胞衔接器
    • NK细胞衔接器
    • 抗体药物复合体
    • 亲和性重定向抗体
    • 双功能抗体
    • 三功能抗体
  • 市场规模及预测：依产品划分
    • 治疗性抗体
    • 诊断抗体
    • 研究抗体
    • 客製化抗体
  • 市场规模及预测：依技术划分
    • 融合瘤技术
    • 噬菌体展示技术
    • 基因转殖小鼠技术
    • 单B细胞技术
  • 市场规模及预测：依组件划分
    • 轻链
    • 重链
    • 锋区
    • 抗原结合位点
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 自体免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究机构
    • 受託研究机构
  • 市场规模及预测：依製程划分
    • 药物发现
    • 发展
    • 製造业
    • 品管
    • 监管部门核准
  • 市场规模及预测：依市场细分
    • 内部开发
    • 外包
    • 杂交种
  • 市场规模及预测：依功能划分
    • 标靶结合
    • 免疫调节
    • 讯号传导
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床试验
    • 市售产品

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Genmab
  • MacroGenics
  • Crescendo Biologics
  • F-star Therapeutics
  • Xencor
  • Zymeworks
  • Affimed
  • Harpoon Therapeutics
  • Immunocore
  • AbCellera
  • Regeneron Pharmaceuticals
  • Pieris Pharmaceuticals
  • Adimab
  • Ichnos Sciences
  • Sorrento Therapeutics

第九章 关于我们

简介目录
Product Code: GIS33684

Bispecific Antibodies Market is anticipated to expand from $12.3 billion in 2024 to $25.6 billion by 2034, growing at a CAGR of approximately 7.6%. The Bispecific Antibodies Market encompasses therapeutics engineered to bind two distinct antigens, enhancing targeted treatment efficacy in oncology, immunology, and infectious diseases. These innovative molecules offer improved specificity and reduced off-target effects. Market growth is propelled by advancements in genetic engineering and increasing cancer prevalence, fostering novel therapeutic development and strategic collaborations among biopharmaceutical entities.

The Bispecific Antibodies Market is experiencing robust growth, propelled by advancements in targeted therapies and immuno-oncology. The oncology segment dominates, with hematologic malignancies leading due to their high therapeutic potential. Solid tumors follow closely, reflecting increasing research investments and clinical trials. In terms of sub-segments, the CD3-based bispecific antibodies are top performers, leveraging their ability to engage T-cells effectively. CD20/CD3 bispecifics are expected to witness significant traction, driven by their efficacy in B-cell malignancies. The autoimmune disorders segment is also gaining momentum, with bispecific antibodies offering novel treatment avenues. Within this, the TNF-alpha and IL-6 targeting antibodies are emerging as promising candidates. Technological advancements in antibody engineering and bispecific formats, such as dual-affinity re-targeting, are enhancing therapeutic efficacy and safety profiles. Strategic collaborations and partnerships among biopharmaceutical companies are accelerating the development pipeline, fostering innovation and expanding the market landscape. The demand for personalized medicine further bolsters market growth.

Market Segmentation
TypeT-cell Engagers, NK-cell Engagers, Antibody-Drug Conjugates, Dual-Affinity Re-Targeting Antibodies, Bifunctional Antibodies, Trifunctional Antibodies
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Custom Antibodies
TechnologyHybridoma Technology, Phage Display Technology, Transgenic Mouse Technology, Single B Cell Technology
ComponentLight Chain, Heavy Chain, Fc Region, Antigen-Binding Site
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
ProcessDiscovery, Development, Manufacturing, Quality Control, Regulatory Approval
DeploymentIn-house, Outsourced, Hybrid
FunctionalityTarget Binding, Immune Modulation, Signal Transduction
StagePreclinical, Clinical Trials, Marketed

Market Snapshot:

The Bispecific Antibodies Market is marked by a dynamic reshaping of market share, driven by innovative pricing strategies and the introduction of groundbreaking products. Companies are increasingly focusing on strategic launches to capture unmet medical needs, enhancing their competitive edge. The market landscape is characterized by a robust pipeline of products, with an emphasis on novel therapeutic areas. This strategic approach is fostering a competitive environment where pricing plays a pivotal role in market penetration and consumer adoption. Competition within the Bispecific Antibodies Market is intense, with leading pharmaceutical giants vying for dominance. Benchmarking reveals a landscape where regulatory frameworks significantly influence market trajectories. North America and Europe are at the forefront, with stringent regulatory standards shaping market dynamics. Asia-Pacific, however, is witnessing a surge in investment and regulatory easing, fostering a conducive environment for growth. The interplay of these factors presents a complex yet promising landscape for stakeholders looking to capitalize on emerging opportunities.

Geographical Overview:

The bispecific antibodies market is witnessing substantial growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and significant investments in biotechnology. The region's strong emphasis on research and development fosters innovation in bispecific antibody therapies. Europe follows closely, with robust regulatory frameworks and increased government funding supporting the market's expansion. The region's focus on personalized medicine enhances its market potential. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditure and increasing prevalence of chronic diseases. Countries like China and India are emerging as key growth pockets, with substantial investments in biopharmaceutical research. Latin America and the Middle East & Africa are nascent markets with growing potential. Latin America benefits from improving healthcare infrastructure and increased access to innovative therapies, while the Middle East & Africa are focusing on advancing their biotechnology sectors to drive market growth and innovation.

Key Trends and Drivers:

The bispecific antibodies market is experiencing robust growth driven by advancements in biotechnology and increasing cancer prevalence. These antibodies offer targeted therapies, enhancing treatment efficacy and reducing side effects, which is propelling their adoption. Key trends include the development of novel bispecific constructs, improving specificity and functionality, and expanding therapeutic applications beyond oncology. Pharmaceutical companies are investing heavily in research and development to create innovative bispecific platforms. This investment is accelerating product pipelines and facilitating faster regulatory approvals. The market is also witnessing strategic collaborations and partnerships, enhancing technological capabilities and expanding market reach. Additionally, the increasing focus on personalized medicine is creating opportunities for bispecific antibodies to address unmet medical needs. Emerging markets are showing significant potential due to rising healthcare expenditure and improving infrastructure. There is a growing demand for advanced biologics, providing lucrative opportunities for market players. As awareness of bispecific antibodies increases, the market is poised for sustained growth, driven by technological advancements and strategic industry alliances.

Restraints and Challenges:

The bispecific antibodies market encounters several significant restraints and challenges. A primary challenge is the intricate manufacturing process, which demands specialized facilities and expertise, thus inflating production costs. This complexity can hinder scalability and limit the ability to meet growing demand. Regulatory hurdles also present a formidable challenge. The stringent approval processes for bispecific antibodies can delay market entry and increase development costs. Companies must navigate a complex landscape of regulations that vary by region, complicating international expansion. The market also faces substantial competition from conventional monoclonal antibodies and other emerging therapies. These alternatives often have established efficacy and safety profiles, making it difficult for bispecific antibodies to gain a foothold. Moreover, there is a shortage of skilled professionals equipped to develop and manage bispecific antibody therapies. This talent gap can slow innovation and impede progress in the field. Lastly, reimbursement issues pose a significant barrier. The high costs associated with bispecific antibodies can lead to challenges in securing coverage from insurance providers, limiting patient access and market growth.

Key Players:

Genmab, MacroGenics, Crescendo Biologics, F-star Therapeutics, Xencor, Zymeworks, Affimed, Harpoon Therapeutics, Immunocore, AbCellera, Regeneron Pharmaceuticals, Pieris Pharmaceuticals, Adimab, Ichnos Sciences, Sorrento Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Component
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 T-cell Engagers
    • 4.1.2 NK-cell Engagers
    • 4.1.3 Antibody-Drug Conjugates
    • 4.1.4 Dual-Affinity Re-Targeting Antibodies
    • 4.1.5 Bifunctional Antibodies
    • 4.1.6 Trifunctional Antibodies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Custom Antibodies
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Hybridoma Technology
    • 4.3.2 Phage Display Technology
    • 4.3.3 Transgenic Mouse Technology
    • 4.3.4 Single B Cell Technology
  • 4.4 Market Size & Forecast by Component (2020-2035)
    • 4.4.1 Light Chain
    • 4.4.2 Heavy Chain
    • 4.4.3 Fc Region
    • 4.4.4 Antigen-Binding Site
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Autoimmune Diseases
    • 4.5.3 Infectious Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Neurological Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Discovery
    • 4.7.2 Development
    • 4.7.3 Manufacturing
    • 4.7.4 Quality Control
    • 4.7.5 Regulatory Approval
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Target Binding
    • 4.9.2 Immune Modulation
    • 4.9.3 Signal Transduction
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical Trials
    • 4.10.3 Marketed

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Component
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Component
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Component
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Component
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Component
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Component
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Component
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Component
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Component
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Component
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Component
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Component
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Component
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Component
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Component
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Component
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Component
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Component
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Component
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Component
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Component
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Component
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Component
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Component
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Genmab
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 MacroGenics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Crescendo Biologics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 F-star Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Xencor
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Zymeworks
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Affimed
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Harpoon Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Immunocore
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 AbCellera
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Regeneron Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Pieris Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Adimab
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Ichnos Sciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Sorrento Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us